AGENDA
MARCH 8-11, 2027
WALTER E. WASHINGTON CONVENTION CENTER, WASHINGTON D.C.
Washington D.C., 30 March 2026 - 2 April 2026
Schedule
Create your personal agenda –check the favourite icon
BIODEFENSE & BIOSECURITY WORKSHOP
- ODEFENSE & BIOSECURITY (AM)Room 201Strategic priorities in domestic & international biodefense & biosecurity
- Strategic Priorities: Outlining the specific threats (e.g., emerging pathogens, select agents, or novel delivery systems) that are driving current policy and planning.
- Investment Areas: Identifying critical funding priorities for the next generation of medical countermeasures, platform technologies, and supply chain resilience.
- Technological Frontiers: Discussing promising new technologies, such as on-demand manufacturing, continuous fermentation for therapeutics, and advanced modeling/diagnostics, that are essential to achieving rapid response capabilities.Moderator: Vic Suarez, Founder and Principal Growth Partner, Blu Zone BioDr Mike Stebbins, Senior Vice President, ATICOL John Nuckols, PhD, JPM CPE-CBRN Medical *TBCMaj Gen(ret) Paul Friedrichs, MD, Senior Adviser, CSIS Global Health Policy CenterDr Kara Schmid, Director, Center for Military Psychiatry & Neuroscience, WRAIRDr Jean-Hu Primmer, Senior Director, Global Regulatory Strategy, Infectious Diseases, Moderna
11.30 – 12.30pm Panel: Redefining Preclinical Development: Non-clinical models to support development and licensure
- Transition from animal models
- Organ-on-a-Chip, In Silico Models & Regulatory Pathways
- Integration of new models into FDA submissions
- Implications for accelerated approvalModerator: Dr Bassam Hallis, Deputy Director, Head of Vaccine Development & Evaluation Centre, UKHSADr Girija Goyal, Principal Scientist, Advanced Technology Team, Wyss InstituteDr Ruth Cheng, CEO, ATCCDr Tom King, VP of Nonclinical R&D, Sabin Vaccine InstituteDr Javier Castillo-Olivares, Preclinical Lead – Coronavirus / Disease X, CEPI
BIODEFENSE & BIOSECURITY (PM)Room 2012pm Afternoon co-chair’s opening remarks: Taylor Sexton, Executive Director, Medical Countermeasures CoalitionDr Matthew Hepburn, Partner, Avinora Health
2:10 – 2.30pm Evolving Role of Next Generation Event Based Surveillance (EBS) in Supporting Outbreak Response and BiodefenseDr Nahid Bhadelia, Founding Director, CEID; Founding Director, BEACON; Associate Professor, Infectious Diseases, Boston University Medical School
2:30 – 2:50pm Ensuring Assay Integrity: The Role of Authenticated Reference Data in BiodefenseJonathan Jacobs, Senior Director of Bioinformatics, ATCC
2:50 – 3:10pm The Rapidly Evolving Funding Ecosystem For BiosecuritySandeep Patel, CEO, Catalyze R&D
3:10- 4:10pm Panel: Biosecurity & Bots: Setting the Guardrails for AI in Vaccine R&D
- Identifying and mitigating the risks of AI "hallucination" and erroneous data in vaccine research and development.
- Establishing oversight and accountability to safeguard AI tools, especially concerning drug safety and efficacy.
- The need for "AI police" or quality assurance to check code and validate AI outputs before they impact clinical trials.
- Discussing the challenge of moving away from manual expertise and the potential loss of human validation in pharmacovigilance and research.
- Examining the biosecurity implications of unregulated AI tools in creating novel molecules and designing preclinical models for vaccines.
- Forecasting Future Biothreats: Integrating AI and Global Surveillance.
- Exploring predictive analytics, AI-driven bio-surveillance, and early warning systems.Hansilla Alaigh, CEO & Founder, Global Action AllianceNikki Romanik, Co-Founder, BioRadar Public Benefit CompanyPatrick Boyle , Interim CSO, ATCCDr Anne Cheever, Founder, Vela Scientific LLC
4:10pm End of Workshop
10:00 – 10:05 Opening RemarksWorkshop Co-Chairs: Taylor Sexton, Executive Director, Medical Countermeasures CoalitionDr Matthew Hepburn, Partner, Avinora Health
10:05– 10:30 Biodefense in Evolution: Trends, Threats, and Strategies for 2026Chandresh Harjivan, Former Special Assistant to the President, The White House, Visiting Fellow, Margolis Institute for Health Policy
10:30 – 11.30am Securing the Nation: Aligning U.S. Strategic Priorities, Investment, and Technology in Biodefense
ANTIMICROBIAL RESISTANCE WORKSHOP
Workshop Chair: Dr Christian Harding, CSO and Co-Founder, Omniose
- 10.00 Chair’s Opening Remarks
- 10:10 Keynote Intro – Impact of Vaccines on AMR
- 10.30 Advancing Immunity: Clinical Development of a Peptide Conjugate Vaccine for Group A Streptococcus
- 10.45 Leveraging Serological Insights to Combat Emerging Pathogens and Antimicrobial Resistance
- 11.00 The Cost of Inaction: Quantifying the Economic Value of Vaccines in the Fight Against AMR
- 11.15 Two Targets, One Construct: Psl-PcrV Bioconjugate Vaccine to Tame P. aeruginosa
- 11.30 AMR, Biodefence and National Security: They’re All Connected
- 12:00 Mitigating AMR in LMICs: The Role of Vaccines in a One Health World
- 12.15 Panel Discussion: Perceptions of AMR Vaccine Development in the Current Global Climate
- 14:00 – 15:00 Funding Pipeline Updates
- 14:00 Gates Foundation
- 14:20Wellcome Trust
- 14:40 Adjuvant Capital
- 15:00- 16:00 AMR Vaccines Development Updates
- 15:00 Applying HIV vaccine design principles toShigella&Acinetobacter
- 15:15Universal Pneumococcal Vaccine Development
- 15:30 From Immunity to Impact: Building Executable Vaccines Against Klebsiella pneumoniae
- 15:45 Advancing a multivalent vaccine candidate to prevent S.aureus skin infections
- 16:00 Panel: Are Combination Vaccines the Way Forward for AMR /Defining the Value of Combo Vaccines?
- Economic valuation of vaccines with reduction on AMR
- Improving coverage of viral vaccines which reduce AMR
- Explore the concept of Syndromic vaccines
ANTIBODIES FOR INFECTIOUS DISEASES WORKSHOP
- TIBODIES FOR INFECTIOUS DISEASE (AM)Room 202BResearch & Development of mAb therapeutics for infectious diseases
- Development of mAbs for infectious diseases
- mAb design
- Reducing the cost of mAb manufacturing
MEASURING BREADTH & EMERGING TARGETS
10:10am A Long Acting Monoclonal Antibody for Seasonal Prevention of Lyme DiseaseDr Mark Klempner, Professor of Medicine & Principal Investigator, University of Massachusetts
10:40am Multiplexed Neutralization Assays: A Unified Platform for Evaluating Breadth Against Priority PathogensDr Nigel Temperton, Chair in Molecular Virology, Director of Research and Innovation, Medway School of Pharmacy, University of Kent
11:00am Developing mAb therapies that keep pace with rapidly evolving viral threatsDr Robert Allen, CSO, Invivyd
TRANSFORMING DELIVERY & CLINICAL ACCESS
11:20 Breaking the Cycle: A Novel Anti-Toxin B Antibody Against RecurrentC. difficileInfectionsDr Christine Tkaczyk, Director, Bacteriology early Vaccines & Immune Therapies, AstraZeneca
11:50am Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVIDDr Laurent Humeau, CSO, Inovio
12:10am The Sepsis Antibody Breakthrough: restoring immune function with hCitH3-mAbDr Jianjie Ma, Professor, Surgery, University of Virginia
12:30pm From Bench to Broad Access: The journey of Nirsevimab, a long-acting mAb against RSVDr Sachin Paranjapi, Sanofi *TBC
1pm NETWORKING BREAK
ANTIBODIES FOR INFECTIOUS DISEASES (PM)
2:00pm Panel: Next-Gen mAbs for Infectious Diseases: Accelerating from Lab to Global Access
- Microbial vs. Mammalian: New platforms for anti-infectives.
- The CMC Bridge: Moving from discovery to clinical-grade manufacturing.
- Clinical Delivery: Long-acting formulations and the shift to subcutaneous dosing.
- Equity & Economics: Practical pathways to the $10/g goal for global access.Moderator: Dr Michael Caldwell, Assoc VP Vaccine Research & Education, Meharry Medical CollegeDr Antonio DiGiandomenico, Senior Director, Head of Microbial Antibodies and Technologies, Early Vaccines and Immune Therapies, AstraZenecaDr Huub Gelderblom, Director, Strategic Partnerships, HVTN, Fred HutchDr Richard Welch, VP BioProcess Development & Manufacturing, IAVI
THE MULTI-SPECIFIC FRONTIER
3:00pm Beyond Monoclonals: Harnessing Recombinant Polyclonals to Future-Proof Against Viral EscapeDr Sheila Keating, Vice President, Immunology, GigaGen
3:20 – 3:40pm Development of unique tetravalent antibodies for COVID and FluDr John Mascola, CSO, Modex Therapeutics
3:40pm Next-Generation HIV mAbs: Optimizing Potency, Duration, and Global AccessDr Jon Heinrichs, Vice President & Head of Discovery Science, IAVI
4:00pm Multi-specific Antibodies and Cocktails: The Future of Complex ID Intervention
- The technical hurdles of discovering, engineering, co-manufacturing and co-formulating multiple mAbs or multi-specific formats.
- Designing mAbs that target multiple mechanisms (e.g., neutralizing toxin and facilitating pathogen clearance).
- Clinical trial design challenges for combination products in infectious disease settings.
- Regulatory challenges
Moderator: Dr Huub Glederblom, Fred HutchDr John Mascola, CSO, Modex TherapeuticsDr Sheila Keating, Vice President, Immunology, GigaGenDr Peter Marks, Head of Infectious Diseases, Eli Lilly
5pm End of Workshop
10am Workshop Chair’s Opening Remarks: Dr Mark T. Esser, Chief Scientific Officer & Head, Paul and Diane Manning Institute of Biotechnology
Topics
VACCINE TECHNOLOGY WORKSHOP
Topics:
- Cutting-edge technologies shaping the future of vaccine development.
- Adjuvants
- AI tools for Protein Design/Epitopes
Workshop Chair: Dr David Burkhart, Chief Executive Officer, Inimmune
10:00 Chair’s Opening Remarks
10.10 Self-replicating RNA Platform Development
10.30 A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious and Non-Communicable Diseases
10:50 Human Lymph Node-On-Chip Microfluidic Platforms for Vaccine and Therapeutic Development
11:10 A Modified Sarna Platform Technology for the Development of A Pan-Filovirus Vaccine
11:30 Killed Whole Cell Genome Reduced Bacterial Vaccines: A New Rapid, Inexpensive, Easily Manufactured, Thermostable Platform
11:50- Q&A
12:00 Panel: The Evolving Landscape of Novel Adjuvant Development – Navigating Safety, Access and Innovation
- Safety as a priority and hurdle for the acceptance novel adjuvants
- How can we further de-risk adjuvants?
- Changing Models in licensing and access, how will non-exclusive licensing change the field?
- Can innovation and adoption of new technologies overcome barriers in cost and access?
CHRONIC DISEASE, AUTOIMMUNITY & THE VIROME WORKSHOP (AM)
CHRONIC DISEASE, AUTOIMMUNITY & THE VIROMERoom 204C
Exploring the drivers and development of vaccines against non-infectious disease targets.
10am Chair’s opening remarks: Please introduce yourself and give a brief overview of the sessions to be covered throughout the day before introducing the speakers on stage for the opening panel.Dr Michael Caldwell, Assoc VP Vaccine Research & Education, Meharry Medical College
10:05am Panel: Adjuvants and Immunity: Exploring Systemic Benefits Beyond Zoster- Beyond Shingles: Explore emerging data linking zoster vaccines to reduced risks of cardiovascular disease and Alzheimer’s.- Immunological Insights: Discuss how zoster vaccines adjuvant systems may drive systemic immune benefits beyond zoster prevention- Correlates of Protection: Identify immune markers that may explain long-term protection and -potential cross-disease benefits.- Public Health Implications: Debate whether zoster vaccines should be recommended earlier in life for chronic disease prevention.- Future Research: Outline next steps for validating these findings and applying the model to other latent viruses like EBV.Moderator: Jay Evans, Chief Scientific and Strategy Officer, InimmuneDr Bali Pulendran, Professor, Director, Institute for Immunity, Transplantation and Infection, Stanford University School of MedicineDr Ofer Levy, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital, Professor, Harvard Medical SchoolDr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford UniversityDr Ken J. Ishii, Director and Professor, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo
11:00 Uncovering the Immune Landscape of Autoimmune Disease: From Parkinsons to ALSDr Emil Johansson, Senior Scientist, Neurodegeneration Program Lead, La Jolla Institute for Immunology
11:30 The shingles vaccine and dementia: A causal relationship?Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University
12:00 Clinical Development of a TLR4 Agonist in Phase 2 Trials for Allergic RhinitisDr Shannon Miller, VP of Operations, Inimmune
12:30 Accelerating Development of Vaccines for Prevention and Control of Alzheimer’s Disease: The Alzheimer’s Vaccine InitiativeTed Schenkelberg, Managing Partner, Next Frontier Advisors
VACCINE DEVELOPMENT PLATFORMS: THE PLAYBOOK FOR GLOBAL VACCINE INNOVATION
10am Chair’s opening remarksPlatforms positioned as strategic infrastructure; importance of early platform decisions on clinical, CMC, and access outcomesDr. Tony D’Amore, Consultant Process Biologics, Premas Biotech
10:10am Platforms Begin at DiscoveryPlatform constraints shaping antigen/target selection; structuring discovery for regulatory pathway readiness and manufacturing scalability; intrinsic platform trade-offs.Dr. Prabuddha Kundu, Co-founder and MD, Premas Biotech
10:30am Platform Validation in the Real World — The PlaybookDefining credible platform validation; minimum data packages; role of independent evaluation; funding and preparedness-linked milestonesDr. Philippe-Alexandre Gilbert, Senior Program Officer, Gates Foundation
10:50am Panel: Evaluating Platform Validation StandardsEvaluating platform validation standards across diseases, species, and regulatory environmentsModerator:Dr. Tony D’Amore, Consultant Process Biologics, Premas BiotechDr Raman Rao, CEO, Hilleman LaboratoriesCharles Kline, Associate Vice President, MerckDr Elizabeth Norton, Associate Professor, Department of Immunology & Microbiology, Tulane UniversityBharat Dixit, CTO, ClearB Therapeutics
11:50 Coffee Break
12pmPanel: Integrated Vaccine Platform Execution ModelIntegrating discovery, validation, engineering, regulatory, and deployment into one execution modelModerator: Dr. Prabuddha Kundu, Co-founder and MD, Premas BiotechDr Gautam Sanyal, Principal Consultant, Vaccine Analytics, LLCDr. Nupur Mehrotra, Founder & Director Operations, Premas BiotechDr. Philippe-Alexandre Gilbert, Senior Program Officer, Gates Foundation
1pm End of Workshop
GLOBAL HEALTH WORKSHOP
GLOBAL HEALTH
Room 209AB
Identifying innovative and collaborative solutions throughout the development pathway to advance Global Health vaccine candidates beyond historical roadblocks. Understanding the factors which influence access and equity in low resource settings.
10:30am Chair’s opening remarks & presentation:
Vaccine Equity—A Historical Perspective and Future Imperatives
Dr Seth Berkley, Senior Advisor, Pandemic Center at Brown University
11am Using a partnership model for peer-to-peer learning and planning to optimize vaccine impact: A case study from Hexavalent Vaccine Implementation in Africa
Dr Kate Hopkins, Senior Director of Research, Vaccine Acceptance & Delivery, Sabin Vaccine Institute
11.20amFrom Capacity to Capability: How LMIC CDMOs Are Becoming Strategic Growth Engines
ALN Reddy, Sr Vice President, Strategic Business Development, Biological E
11:40am
Innovative Adjuvants for Global Health
Peter Tygesen, Business Development Director, SPI PharmaJuhienah Khalaf, Director of Chemistry, InImmune
12:00pm
Enhancing Adjuvant Availability: An Open-Access Model for Global Health
Dr Gerben Marsman, Head of Alliance Management, Vaccine Formulation Institute
12:20pmAdjuvants at Scale: Sustaining Global Demand
Damien Hiley, Partner & Managing Director, Desert King
1pm – 2pm Networking Break
GH Vaccine Development Updates:
2:00pm Development Updates for NTD VaccinesDr Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
2:20pm Early development of a blood-stage, whole parasite vaccine for malaria
Dr Michael Good, Principal Research Leader, Head, Laboratory of Vaccines for the Developing World, Griffith University
2:40pm New Tuberculosis Vaccines – update and latest developments
Prof Richard White, Prof of Infectious Disease Epidemiology, LSHTM; Co-chair, Collaboration for TB Vaccine Discovery EMTD Research Community; WHO TB Vaccine Technical Advisory Group
3:00pm Fireside chat: The 96% Solution: Transforming the Fight Against Malaria Through Unprecedented Maternal and Infant Protection
· The Global Crisis: Addressing the critical need for next-generation malaria vaccines due to increasing cases and the limitations of current solutions.
· Breakthrough Data: Unveiling the "dream come true" results showing 96% protection against clinical malaria in infants born to mothers vaccinated pre-conception.
· Maternal Immunity: Examining the implications of long-lasting, transferred maternal immunity as a game-changer for infant survival.
· Policy and Elimination: Discussion on how this high, durable efficacy impacts global health policy, funding, scalability, and the path to malaria elimination.
Moderator: Dr Stephen Hoffman, Chief Executive and Scientific Officer, Sanaria
Dr Patrick E. Duffy, Chief, Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH, Bethesda, MD USA
Ambassador John Simon, Managing Partner, Total Impact Capital, Bethesda, MD, USA
3:45pm -4:45pm Panel: How Vaccine Access Differs Across Countries—and What to Do About It
· Examine how systems shape vaccine access from development to delivery.
· Contrast vaccine pathways in high- vs. low- and middle-income countries.
· Highlight barriers like trial investment gaps and delayed approvals.
· Share strategies from global experts to improve equitable access.
Moderator: Anna Larson, Advisor, Epstein Becker & Green
Rebecca Martin, President, Global Immunization, Sabin Vaccine Institute
Larry Kerr, DVP, Global Health & Multilateral Affairs, PhRMA
Chris Colwell, VP, International Government & Regulatory Affairs, USP
Dr Rajeshwari Adhiseshan, Senior Program Officer, Gates Foundation
Chloe Cooney, Director, US Strategy, Gavi, The Vaccine Alliance
5pm -End of Workshop
UNCONVENTIONAL VACCINES: OBESITY, ATHEROSCLEROSIS, AND ALZHEIMER’S DISEASE
This workshop explores the cutting edge of vaccinology, moving beyond infectious diseases to tackle the world’s most pressing chronic and metabolic conditions. Hosted by 3H Bio, the session brings together global pioneers to discuss how targeted immunological interventions can arrest the progression of atherosclerosis, Alzheimer’s, and obesity.
Attendees will gain insights into:
- Clinical breakthroughs in Tau-targeting vaccines for neurodegeneration.
- Novel platforms like mimotope vaccines for metabolic regulation.
- Translational challenges of moving unconventional vaccines from immunological theory to human clinical trials.
Join us to discover how the next generation of vaccines is being engineered to treat non-communicable diseases and reshape the future of preventative medicine.
11.30am Chair’s opening remarks:
Dr Kevin Killeen, President & CEO, 2K Biologics
11:30 Atherosclerosis Vaccination: From Immunological Concepts to Clinical Translation
Dr Jan Nilsson, Professor of Medicine, Lund University
11:50 Advax-CpG adjuvanted Alzheimer’s vaccines
Dr Nikolai Petrovsky, Founder & Research Director, Vaxine
12:10 3HOTP – A mimotope vaccine with anti-obesity and broader metabolic benefits
Dr Bert Binas, CSO, 3H Bio
12:30 Closing Panel Discussion – Common themes and challenges in unconventional vaccine development
VACCINE DELIVERY WORKSHOP
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
2pm Chair’s Opening Remarks: Vaccine Delivery Landscape Overview
2:15pm -4:00pm Vaccine delivery presentations:
- 2:15 Getting Vaccine Efficacy Right Begins With The Right Vaccine Adjuvant
- 2:30 Needle-free Delivery Solutions Addressing Today’s Vaccine Hesitancy
- 2:45 An Adaptable Formulation Platform Enabling Thermostability and Mucosal Delivery Across Biologic Modalities
- 3:00 Where Skin Meets Science: Transforming Vaccination Through Dermal Delivery
- 3:15 Application of Next Gen Tools Including Alternative Delivery Systems and AI To Vaccine and Adjuvant Development
- 3:30 Progress Towards a Clinical IntranasalKlebsiella Vaccine
- 3:45 Nucleic Acid Vaccines: Innovative Molecular Adjuvant Applications for the Elderly To Boost Durability And Efficacy Using Clostridioides difficile As a Model
4:00 Panel: Targeting Mucosal Surfaces in Respiratory Vaccine Development
- Inducing mucosal IgA and T cell immunity
- Formulation challenges for nasal and inhaled delivery
- Applicability to flu, RSV, TB and COVID vaccines
- Prospects for mucosal combo vaccines.
SAFEGUARDING VACCINE ACCESS: NAVIGATING POLICY SHIFTS AND EMERGING ISSUES
Moderator: Citseko Staples Miller, Managing Director, Public Affairs, FTI Consulting
Speakers:
Andy Chasin, Vice President, Federal Policy and Advocacy, Blue Shield of California
Jeff Reczek, Partner, TDY@FGS; Former Director of CDC, Washington
Anita Patel, MD, Pediatrician, Children’s National Medical Center
FORGING OUTBREAK-READY VACCINE PARTNERSHIPS: EBOLA, LASSA FEVER AND BEYOND
- ERVIEW
- Dr Amin Khan, Chief Science Adviser, Afrigen Biologics & Vaccines
- Dr Michael Schunk, Senior Industry Specialist, Vaccines and Biopharma, International Finance Corporation
- Dr Kent Kester, Executive Director of Vaccine Research and Development, CEPI
3:40–4:00pm: Audience Q&A and Closing Remarks by Dr Rao
Pandemics and outbreaks of diseases like Ebola and Lassa fever demand more than just scientific excellence — they require fast, adaptive and resilient partnerships.
Hilleman Laboratories and the International Vaccine Institute (IVI) are convening this workshop to share opportunities and lessons for successful outbreak-ready partnerships in vaccine development.
Format-wise, three case study presentations will be followed by a forward-looking panel discussion covering how to work together on product-level innovation, regional ecosystems and pandemic responsiveness.
AGENDA
2:00–2:10pm: Chair's Opening Remarks – Setting the Scene for Adjustable Innovation--Dr Raman Rao, CEO, Hilleman Laboratories
2:10–3:15pm: Case study presentations:
1. ERVEBO Ebola Vaccine – Genesis and What Next--Ms Kay Hunsberger, Executive Director, External Development, Merck Sharp & Dohme
2. ACHIEVE Africa 2.0 – Building an Outbreak-Responsive Partnership Ecosystem
Dr Sushant Sahastrabuddhe, Associate Director General, IVI
3. IVI-Hilleman Strategic Partnership -Decentralization and Acceleration for Pandemic Response
Dr In-Kyu Yoon, Deputy Director General, Integrated Development & Pandemic Readiness, IVI
3:10 - 3:15Chair’s Transitional Synthesis
Dr Raman Rao, CEO, Hilleman Laboratories
3:15–3:40pm: Panel: Opportunities and Lessons for Successful PartnershipsModerator:Erlyani Hamid, Strategy and Operations, Hilleman LaboratoriesSpeakers:
Create your personal agenda –check the favourite icon
Welcome to the congress
Chair’s Opening remarks & Keynote Address: "The Symphony of Vaccinology: Five Movements”
Keynote panel: Navigating the Crowded Respiratory Disease Season, How Are We tackling Flu, COVID, RSV, hMPV?
· How has the respiratory season evolved? Co-circulation of respiratory pathogens, duration of the respiratory disease season, what are the dominant pathogens?
· Where are we seeing innovation in vaccines for respiratory diseases?
· How are we progressing with prophylactic antibodies, combination & universal respiratory vaccine approaches?
· Uptake for Flu, RSV, COVID vaccines. Are we seeing vaccine fatigue from a crowded schedule?
· Globally evolving regulatory and policy landscape
Micron BioMedical Book Signing with Dr Seth Berkley: "Fair Doses: An Insider's Story of the Pandemic and the Global Fight for Vaccine Equity"
Meet Dr. Seth Berkley and opportunity to receive a signed copy ofFair Doses compliments of Micron Biomedical!
Working Group 1 - Implementing Controlled Competitive Enrollment for High Quality, Rapid Delivery
Working Group 2 - Successful Execution of Pragmatic Trials
Working Group 3 - The Challenges with Challenge Studies: How to Generate Findings Worth Finding?
Working Group 4 - Assays from Discovery to Deployment: Aligning Speed and Science with Regulatory Standards
Working Group 5 - Vaccine Trials: How AI shifts execution from static plans to living systems
From Geneva to the Globe: Transitioning Global Health Leadership & Governance in Vaccine R&D and Immunization to Regional and National Actors
- li>
- How can PPPs best be leveraged?
- What does an optimal global health governance model look like in practice? Multi-layered and decentralized.
- What are the risks and opportunities of transitioning global health governance to new models?
- How can regional institutions be empowered and resourced effectively?
- How can health leadership support countries transition?
Keynote Panel: New Developments in Long-Standing Global Health Challenges Disease. A focus on TB, MALARIA & other NTDs
· Tuberculosis:
- Current TB Vaccine pipeline
- Can we accelerate clinical trials?
- Potential health and economic impact in LMICs
- Progress toward licensure and implementation
- Will demand/supply/funding be available?
· Malaria:
- Vaccine deployment: Lessons from RTS,S and R21 rollouts.
- Vector control: Innovations to address insecticide resistance.
- Climate impact: Adapting to changing transmission zones.
- Sustained funding: Ensuring long-term support for endemic disease control.
·HIV
- Vaccine & Biomedical pipeline: vaccine & bNAb Pipeline, PrEP, research to implementation
- Implementation Readiness & Access: Novel tools in LMICs, sustaining treatment & prevention gains, funding sustainability
- Strategic and societal frameworks: Global strategy & political will, integrating lessons for future epidemics
Working Group 10 - Trust, Technology & Trial Access: Redefining the Vaccine Recruitment Playbook in 2026 & Beyond
Working Group 6 - Straight from the source: Community perspectives on vaccine development in the new era
Working Group 7 - Global Disease Surveillance in the AI Era: Maximizing Insight, Managing Risk
Working Group 8 - Gaps Between Testing and Access to Targeted Therapies
Goal: Identify bottlenecks and propose solutions for faster patient access
Working Group 9 - Unmet Needs in Carrier Protein Development
Networking Break
1:10 – 2:30 1-2-1 Partnering
1:30 – 2:20 Start-up pitches
2:00 – 2:30 Poster Presentations
5-Minute Presentations - Innovator Showcase
1:30 - Dr Yimy Mena, CEO, Pegasus Biotech
1:35 -"Precision Virology Products for Advanced R&D and Product Manufacturing" Dr Nishank Bhala, Senior Scientist/Co-founder, Advanced Virology
1:40 - “Reinventing Stability: A Simplified Approach for Vaccines, Biotherapeutics, and CriticalReagents” Mary Retzlaff, CSO, Ambient Biosciences
1:45 - "Measuring Vaccine Equivalence"DrKyle Berg, R&D Manager, Quansys Biosciences
1:50 -"Fixing the Data Handoffs That Slow Drug Development"Justin Byers, CEO, Axio BioPharma
1:55- "A Breakthrough Synthetic Vaccine Platform"Robert Forgey, President & CEO, IASO Therapeutics
2:00-"Blue Lake Biotechnology: Reinventing Vaccines"Biao He, CEO, Blue Lake Biotechnology
2:05- "A Novel Class of Immunotherapeutics to Confer Broad-Spectrum Protection Against Bacterial and Viral Infections"Dr David Anderson, Founder, Phoenix Therapeutics
Keynote Address: Evidence Endures: Independent Leadership for Vaccine Policy
Keynote panel - Stronger Together: Vaccine Industry Leadership Vision for Next-Gen Vaccines & Global Collaboration
· 2026 key disease focus areas for vaccine manufacturers, upcoming approvals 2026
· What next generation vaccine platforms have the most impact/potential – why?
· Strengthening public-private collaborations – new partnership opportunities of interest
Keynote Address: AI and the Global South: Opportunities and Guardrails in Vaccine Innovation
Keynote Panel: Resilient, Sustainable, and Decentralized: The Future of Global Vaccine Manufacturing
· Sustainability in Manufacturing
o How are manufacturers integrating green technologies? What are the trade-offs between sustainability and cost in LMICs?
· Regulatory Harmonization & Tech Transfer
o What frameworks are needed to streamline cross-border approvals? How can WHO, AVAREF, and regional blocs support harmonization?
· Decentralized & Modular Manufacturing
o What are the benefits and limitations of mobile/modular units? How can these models be deployed in outbreak-prone or remote regions?
· How are different regions evolving?
Keynote closing panel: Future-Proofing Health – Vaccines Against Climate Threats, Food Insecurity, and AMR
- How can vaccination contribute to our broader global health and sustainability agendas?
- Rethinking our approach from response to prevention: mitigating the effects of climate change and reduction of AMR through vaccination
- The effect of climate change and emerging pathogens on food security, is safeguarding livestock and agricultural productivity shaping vaccine prioritization and funding decisions?
Senior Leadership Representative, WOAH (Dr Emmanuelle Soubeyran, Director/ Dr Montserrat Arroyo Kuribreña Deputy Director, WOAH)
Senior Representative, GSK *TBC
Derrick Sim, Managing Director of Vaccine Markets & Health Security, Gavi *TBC
Dr Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena; Coordinator, European Vaccine Hub* TBC
Create your personal agenda –check the favourite icon
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s opening remarks
Fireside chat: Vaccine Law in Crisis: Safeguarding Public Health Amid Regulatory Rollbacks and Legal Challenges
- Legal risks from changes to ACIP and vaccine recommendations
- Impact on vaccine access, funding, and manufacturer liability
- How political shifts are reshaping public health protections
- What legal challenges and reforms may lie ahead?
Panel: Unlocking the Sustainable Use of Pandemic Platforms
- Designing platforms with sustainable use in mind
- Scaling up pandemic platforms – what are the remaining bottlenecks?
- How can ‘pandemic platforms’ be adapted to combat high burden or neglected diseases?
- Enabling manufacturing in LMICs to respond to outbreaks and strengthen routine immunization
High-Resolution Antibody Profiling: Using Next-Generation SPR to Guide and Refine Malaria Vaccine Antigen Design
Panel: CD8 T Cells Without Vectors: The Future of Cytotoxic Immunity
- Explore how emerging platforms (e.g. saRNA, DNA, nanoparticles) can induce CD8+ T cell responses without viral vectors.
- Discuss why CD8+ T cells are critical for vaccines targeting cancer, HIV, and chronic infections.
- Importance of antigen processing via proteasome for CD8 activation.
- Examine the immunological signals and delivery strategies needed to drive durable cytotoxic responses.
- Debate the future of CD8-focused vaccine design in a post-vector era.
- Challenges with RNA-based vaccines (e.g., slippage, inflammation).
- Debate on neoantigen selection, vaccine formulation, and delivery vectors.
Universal Flu Vaccines
Biothreats Emergence, Analysis and Communications Network (BEACON) – An Improved Alert System For Emerging Infectious Diseases
Is an Obesity Vaccine Still Possible – or Has the Science Moved On?
Abstract: Obesity remains one of the most pervasive global health challenges, affecting more than one billion people worldwide and driving rising rates of cardiometabolic disease. While GLP‑1–based therapies and other anti-obesity medications have transformed treatment in recent years, the concept of an “obesity vaccine” continues to generate both scientific curiosity and public debate. Is such a vaccine still feasible?In this session, Dr. Deon Miller, Board-Certified Emergency Medicine Physician, Diplomate of the American Board of Obesity Medicine, and seasoned Principal Investigator with more than 40 clinical trials, will explore the landscape of immunology, metabolism, and vaccine research as it relates to obesity. She will also discuss the potential benefits and risks of an obesity vaccine.Bridging her acute-care background with her metabolic health expertise, Dr. Miller provides a balanced, clinically grounded perspective on where vaccine-based obesity interventions stand today, and whether they could meaningfully complement or even reshape future obesity treatment strategies.
Panel: Living Facilities: Adaptive, Multi-Modal Plants That Shift Between Vaccines in Weeks
Can a modern vaccine plant truly flip modalities—viral vector to mRNA to recombinant protein—in less than 30–60 days without compromising productivity or quality?
Panel: One Health Strategies for Smarter Disease Prevention and Control
- Where can improved coordination between animal and human health sectors accelerate vaccine development and delivery?- In what ways can cross-sector collaboration unlock better use of existing tools — vaccines, diagnostics, digital platforms, and cold chain infrastructure?- How do we fund prevention when benefits are shared, but budgets and responsibilities remain siloed?
Moving Forward: Strategies and Areas of Interest for Industry Partnerships and Collaborations in the New Vaccine Climate
The INSIS Metacohort Vaccine Safety Study: a paradigm for clinical and immune AEFI profiling
The Future of US Non -clinical Vaccine Delivery: Lessons from Global Vaccine Distribution and Administration
- li>
- Bridging procurement and regulatory frameworks.
- WHO’s role in harmonization and technical support.
- Innovative models for funding vaccine production, distribution, and delivery.
- Role of multilateral donors, development banks, and public-private partnerships
T Cell Immunity to Group A Streptococcus: Uncovering Promising Vaccine Candidate Targets
Pandemic Flu Vaccine Development
IXCHIQ®: Striving For Global Access - Real World Evidence Data Generation
Innovation in Trial Risk Management: Managing the Yellow Before the Red
Scaling Biologics Value Chain from Local Discovery and Development in Montgomery County, Maryland, to Global Deployment
LION-formulated saRNA: safety and tolerability update
Panel - State-Level Responses to Shifting Federal Vaccine Guidance
- li>
- Overview of current updates in state policy
- How are federal policies changing state-based implementation of vaccine programs?
- How does a patch-work system affect access?
UniFluVec: A Next-Generation Intranasal Universal Influenza Vaccine Platform
Reducing Risk and Enabling Scalable Viral Vaccine Manufacturing Through Serum-Free Media
Senior Representative, Thermo Fisher
Preclinical Safety and Myocarditis Modeling: Differentiating Next-Gen RNA Platforms
Panel: Chikungunya & Mosquito-Borne Vaccines: Bridging Outbreak Response, Manufacturing, and Market Creation
- li>
- Outbreak Trends: Chikungunya and mosquito-borne disease surveillance in East Africa and South Asia.
- Vaccine Development: Manufacturing, licensing, and safety insights from CEPI-funded initiatives.
- Policy Challenges: Regulatory hurdles and off-label use in outbreak response settings.
- Market Creation: Strategies for demand generation, stockpiling, and Gavi inclusion.
Enhancing Influenza Vaccines Through Technology and Innovation
Throughput Challenges in Influenza Seasonal and Pandemics: The Role of Automation
Systems Biology Approaches to Vaccine Response Prediction Using Large-Scale Immune Profiling Resources
LNP Development for mRNA Cancer Vaccines
A Live Attenuated, Minimally Replicative MPOX Vaccine
Phage Vaccines and the Future of Antimicrobial Resistance Control
Aiming for Success in Poultry Vaccination – OFFLU’s Avian Influenza Matching (AIM) Initiative
- Present the AIM project and its impact on avian influenza vaccine selection for animals.
- Showcase how the OFFLU network supports the development of effective animal vaccines.
Global Vaccine Partnerships Case Studies: Partnering with the Government of Victoria to advance mRNA vaccine development
Detection Is Too Late - Preventing Duplicate & Professional Participants Within and Across Sponsors to Enhance Patient Safety and Protect Vaccine Trials from Failure. A Quality by Design Initiative
Performance and application of Immucise™ Intradermal Injection System, exploring new possibilities for cancer therapy
Simply Complicated: Challenges and Solutions in pH Measurement for Pharmaceutical Quality Assurance
Annual Adaptation of a Recombinant Protein COVID-19 Vaccine: Process, Challenges and Opportunities
Sustaining the Preparedness Engine: Commercial Viability of Dual-Use RNA Platforms
Strengthening CEPI’s Mpox Correlates of Protection (Cop) Framework
Defining and Targeting the Adenosine/Adenosine Deaminase-1 Axis in CD8+T Cell Dysfunction and application to cancer immunotherapy
A Decade Of H3N2 Expertise Driving a Breakthrough in New RSV CHIM Model
Leveraging Real-Time Seasonal Respiratory Disease Insights to Guide Site Strategy and Monitor Outbreak Trends
Senior Representative, Syneos Health
VAERS 2.0, re-evaluating vaccine safety in the era of AI
The Role of Host-Cell DNA Analytics in Optimizing Your Bioprocess Performance
Senior Representative,IDT Biologika
From Farm to Fork: How Animal Vaccines are the Unsung Heros of Human Food Safety
Stronger Together: Powering Vaccine Trials Through Solid Partnership
Addressing persistent misconceptions about how mRNA vaccines work
Vaccine Supply and Demand in Latin America & the Caribbean: Insights from IFC’s Regional Study
The Ripple Effect: Understanding ACIP's Decisions and Their Impact on US Immunization Policy and Access
- li>
- What are the impacts of changes at the ACIP?
- Guaranteeing coverage
- Changes to childhood vaccine schedule
- What does it mean for pharmacists
- What does it mean for patient access?
Routine Vaccination to Support Access and Pandemic Preparedness
Rethinking Vaccine Delivery in Oncology: Positive Clinical Outcomes with Needle-Free Delivery
Standardized Serology: A Cornerstone for Vaccine Licensure and Pandemic Preparedness
Senior Representative, VisMederi
H5N1 Vaccines for Cattle, New Vaccines
Bridging the Gaps in our National Health Security, Aligning Federal Policy and Incentives
Despite major scientific and technological advances, persistent gaps in federal policy and incentives continue to limit the translation of innovation into scalable, reliable, and rapid-response health security capabilities. This session examines where current policy frameworks fall short—across research prioritization, procurement, and manufacturing sustainment—and how misaligned incentives undermine readiness between emergencies. This talk explores a range of policy options to institutionalize preparedness, strengthen coordination across the R&D and acquisition lifecycle for MCMs, and provide clearer signals that accelerate time-to-impact for vaccines and MCMs in the face of high-consequence biological threats.
Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy
TG4050, an Individualized Neoantigen Therapeutic Vaccine in early-stage cancer treatment
Optimizing Cell-Based Vaccine Production Through Advanced Raw Materials
Tackling Tomorrow’s Threats: Innovation to Address Emerging Pandemic Potential Influenza And Re Emerging Poliovirus
AI and the future of vaccine studies from reaction to readiness
QC on Wheels: The Future of Release Testing
Senior Representative, ReciBioPharm
Panel: Addressing Innovation and Jumpstarting New Projects - The Value & Impact of Product Development Partnerships
- li>
- Enhancing the PDP Model for Global Access: How can product development partnerships (PDPs) be optimized for sustained vaccine affordability and accessibility in LMICs?
- Bridging the R&D Valley of Death: What specific strategies can accelerate the translation of basic research discoveries into viable clinical-stage vaccine projects?
- Strengthening Local Biomanufacturing: How can international collaborations effectively transfer technology and build sustainable vaccine manufacturing capacity in LMICs?
- Evidence-to-Policy Implementation: What mechanisms are needed for rapid integration of vaccine R&D data and evidence into national and global health policy decisions?
- Sustainable Financing for Neglected Diseases: How can diverse funding streams (public, private, philanthropic) be secured to de-risk high-priority, non-commercial vaccine innovation?
The value of Brighton Collaboration (BC) case definitions (CD) in observational data
- When the BC was formed in 2000, the basis for developing and using standardized CD's for improving precision of vaccine safety studies was based on methodologic arguments.
- What is the actual scientific evidence since, especially from post-licensure surveillance during the COVID-19 pandemic, for their value?
- How can this evidence for the value of BC CD's contribute to regulatory decision making?
- How can the use of BC CD's be further optimized?
Panel: Rethinking Vaccine Supply Chains to Build Sustainable, Locally-Led Immunization Systems
- Building and adapting to increased regional and domestic immunization systems - How are we transitioning vaccine supply and logistics operations for an expanded portfolio and life course vaccination?- Integration of vaccines into medical supply chains- Strategic partnering and sustainable funding approaches to support national immunization strategies and countries graduating from GAVI support.
RNA Based Vaccine in Animal Health: Affordable and Accessible
Achieving Synergy Between Brighton Collaboration (BC) Case Definitions (CD) and MedDRA Terminology
- MedDRA (Medical Dictionary for Regulatory Activities) is an international, standardized medical terminology used to classify and share information about medical products (including vaccines), especially for adverse event reporting and safety monitoring.
- Past efforts to achieve synergy between BC CDs and MedDRA have been relatively unsuccessful
- Synergy is being identified and public health impact is being evaluated at the intersection of data science, clinical medicine, and epidemiology best practices.
Addressing the Threats to Childhood and Adult Vaccination
- ile threats to pediatric vaccination have captured the headlines there remain real threats to vaccination across the lifespan impacting health equity.
- Panel will examine:
- Parental / patient choices, trust in providers and providers’ trust in vaccines
- Impacts of the rhetoric regarding vaccine policy changes on uptake and access.
- How adult vaccination benefits from strong recommendations, pharmacy access, and clinical support
- Federal policies effect on the Vaccines for Children Program
- Changes needed within state Medicaid programs to supplant VYF if necessary in future
- Goal: identifying cross-cutting strategies to strengthen vaccination across the lifespan.
Accelerating the Creation, Scale-Up, And Delivery of Self-Replicating RNA (Srrna) Therapies Medicines
Senior Representative, Cytiva
Accelerating vaccine immune profiling with multiplexing solutions for serum and single-cell analysis
Targeting mKRAS with ELI-002 Cancer Vaccine – clinical updates *Title TBC
Nasal Vaccines that Induce Robust Mucosal Secretory IgA can Prevent SARS-CoV-2 and Influenza Virus Infection
Jynneos (MVA-BN): An Overview of Clinical Experience and Real-World Use
Senior Representative, Bavarian Nordic
Delivering Vaccine Clinical Trials in Africa: Lessons from Building High-Quality, Scalable Trial Networks
Advancing Adjuvant Innovation Into Robust, Reliable Supply Chains
Building a Future of Vaccine Trust Through Transparency and Innovation – A Publisher’s Perspective
Streamlining Process Development of RNA Capping Using Vaxarray 5’capq and HPLC-Based Methods
Advancing Inactivated Rotavirus Vaccines: From Microneedle Delivery to Global Commercialization
From Awareness to Action: Transforming Trial Enrollment * Title TBC
Biomanufacturing Reinvented: Powering the Future of Medicine
Catalyzing Change: How Investment in the Livestock Sector Drives Pandemic Prevention and One Health Outcomes
5-Minute Presentations - Innovator Showcase
1:10 - "Next-generation Genetically Engineered Bacterial Vaccines"Dr Julie Zhou, Head of Corporate Development, Delonix Bioworks
1:15 - “A First-in-Class Therapeutic Vaccine for Chronic Inflammation”Sean McLoughlin,CEO,Denteric
1:20 - "From Nose to Mouth: Intranasal Vaccination to Prevent Dental Caries and Periodontitis"Dr Ivo Ploemen, Co-Founder & Co-CEO, Praetorian Bio
1:25 - 'Transforming Viral Immune Surveillance & Drug Discovery'Linda D. Chilin, MS,Associate Research Scientist,AthariBiosciences
1:30Asel Sartbaeva,CEO,Ensilitech
1:35 - "TollereBio. Better Adjuvants. Better Health"Dr Robert Ernst, Founder & SAB Chair,TollereBio
1:40PattyTawardos,CEO,Donor X
1:45 - "Innovations in tuberculosis vaccines for bovines"Luana Moraes,Project Manager,BCGene
1:50Gregory Smith, President,ThyreosVaccines
1:55 - "Building the Future of Bacterial Prevention: Advancing Phage Prophylaxis for Cholera"-DrMinminYen,CEO & Co-Founder,PhagePro
2:00Professor Juliane Bubeck Wardenburg,Founder,Forward Defense LLC
Chair’s Opening Remarks
Scaling What We Know: Integrating Prior Knowledge to Power the Next Generation of Vaccines
Leveraging Spectral Flow Cytometry to Get the Most out of Early Phase Clinical Trials
Advancing Dark-Genome Derived Tumor Targets into Clinical-Stage Products
- li>
- Target selection: consistently identifying the most immunogenic highly shared tumor epitopes across the full genome
- Construct design: Finalized technology blocks for String of Beads construct design and mRNA optimizations
- Product design: Evaluating mRNA and LNP modalities with Arcturus Therapeutics
- Clinical entry: Both myNEO personalized and off the shelf products received IND approvals and are entering the clinic
RSV-hMPV-PIV Combination Vaccine Efficacy Testing Platform
Senior Representative, hVIVO
Versatile Microneedle Vaccine Delivery Platform and Agile Manufacturing to Combat Emerging and Re emerging Infectious Diseases
Panel: From Vial to Volunteer: How Early Decisions Make or Break Trial Timelines
Two Case Studies of Vaccine Development using Simple Western™ Technology: V590 COVID Vaccine HCP Content and V937 Coxsackievirus Vaccine Full and Empty Particle Analysis
Senior Representative, Merck
Science Is Not Enough: Rethinking Risk and Return in Vaccine Communication
How to break down barriers in communication with policymakers, staffers, and the general public, especially around animal interventions and research in the face of vaccine hesitancy
Panel: Public-Private Partnerships for Pandemic Readiness & Biosecurity: Models That Work
- li>
- Frameworks and pre-agreements for rapid mobilization of public and private resources
- Case studies of successful PPPs (e.g., COVID-19 vaccine partnerships)
- Aligning incentives and access obligations across sectors and funders
- Evolving global funding roles and the impact of the Pandemic Accord
- Building resilient partnerships to ensure equitable innovation and deployment
Revisiting Thimerosal – A Case Study in Vaccine Safety and Public Perception
- li>
- Re-examine the scientific evidence surrounding thimerosal and neurodevelopmental outcomes.
- Explore how misinformation and politicization shaped public perception and policy decisions.
- Reflect on the implications of recent ACIP actions and the normalization of anti-science rhetoric.
- Discuss the global relevance of thimerosal, especially in LMICs where multi-dose vials are still used.
UNICEF’s Sustainable Procurement of Vaccines: Towards More Environmental Sustainable Vaccine Manufacturing and Supply
Panel: Vaccines and Value: Navigating Care, Cost, and Controversy in a Shifting Policy Landscape
- li>
- Why vaccines are essential to value-based, person-centered, prevention-focused care
- The importance of vaccine insurance coverage and potential impact of ACIP changes
- Vaccine cost-effectiveness and the impact of pricing
- Physicians’ strategies for addressing vaccine hesitancy
- The intersection of public health and health system sustainability
Next Generation Tissue Selective Lipid and Polymer-Based Selectivity Enabling Nano Shell (SENSTM) Technology Optimized for Prophylactic and Therapeutic Applications
Leveraging CRISPR-Cas9 for a Next-Generation Malaria Vaccine
Synthetic Adjuvants: Facilitating Accessible and Scalable Global Vaccine Development
Next Generation Pandemic Vaccine Development
Functional Antibody Immunity: Moving from Binding Profiles to Fc-Driven Mechanisms of Protection
Personalized Cancer Immunotherapy Targeting Low Tumor Mutational Burden Cancers
From Seasonal Flu to HPAI: End-to-End Virology Capabilities Built for Speed, Rigor, and Readiness
Senior Representative, Microbiologics
Seeing the Whole Picture: Why Phenotyping Is Critical During Vaccine Development
A Standout Advantage: High quality results delivered with speed and scale
Enabling Combination Adjuvants Via Synthetic Biology
A Scalable Vaccine Solution for the Current H5 Panzootic: Cross Clade Protection and Reduced Transmission
Ebola: Conducting clinical trials in the midst of an outbreak
- li>
- Safety monitoring during trials in politically unstable regions (e.g., Congo, Uganda).
- Post-licensure surveillance in outbreak settings
Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery
- li>
- Scaling Innovation: Expanding novel delivery formats in LMICs needs strong public-private partnerships and tech transfer.
- System Readiness: Promising technologies face adoption barriers due to limited infrastructure and regulation (PPP and tech-transfer). Are health systems and delivery programs equipped for novel formats?
- Formulation Focus: Adjuvants and formulation science are key to effective, scalable needle-free platforms.
- Strategic Coordination: Aligning science, strategy, and scale-up is vital to move innovations into practice.
Advancing Self-Amplifying RNA for Respiratory Viruses: Bridging Breadth and Safety
Panel: Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity
From Variant Detection to First Patient Dosed in days: How Technology and Changing Regulations are Rewriting the Vaccine Trial Playbook
Enabling Global Vaccine Innovation: An Integrated CDMO Platform from Development to Commercial Supply
Panel: Old Foes – New Vaccines: Innovation in Veterinary Vaccines
- New approaches to longstanding diseases: African swine fever, Avian influenza.- Improving our understanding recombination, immunology and vaccine targets.- How do we define and measure "impact" in the absence of sterile immunity – DIVA vaccines?- Innovative delivery systems including microneedle patches, intranasal, and oral platforms for mass vaccination- Multivalent vaccine development: navigating formulation, stability, and immune interference across species
Vaccine Protection and Productivity: The Economic Value of Vaccines
Self-Amplifying mRNA: Opportunities for Development of Vaccines Against Complex Biological Targets
Characterization of Bcfa, an Adjuvant That Drives TH1/TH17 Immunity and Enhances Protection at Mucosal Sites
SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
From Paper to Progress: How CRIO Central eSource Accelerates Vaccine Trial Execution
The Potential of Novavax’s Technology Platform, including Matrix-M® adjuvant
Influenza’s Economic Burden and the Impact of Adult Vaccination
International Vaccine Bio-clusters
3:50 India - The Bangalore Bioinnovation Centre (BBC) *Title TBCDr Mohamed Adil, Managing Director, Bangalore Bioinnovation centre (BBC)
4:00 Italy – Italian investment in pandemic preparednessDr Gianluca Polifrone, General Director, Fondazione Biotecnopolo di Siena
4:10 Japan - International Vaccine Design CenterDr Ken J. Ishii, Director and Professor, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo
4:30 Canada – Health Emergency Readiness CanadaRitu Banerjee, Assistant Deputy Minister, Health Emergency Readiness Canada
4:40 Australia - Building an End-to-End RNA Ecosystem to Accelerate Vaccine DevelopmentDr. Andrew Hastings, Senior Advisor and BioNTech Project Lead, Victoria State Government, Australia
4:50 USA – Montgomery County Economic Development CorporationMarc Elrich, County Executive, Montgomery CountyJudy Costello, Director of Economic Development and Special Projects, Montgomery County
5:00 Beyond Borders: The European Commission’s Role in Orchestrating a Pan-European Vaccine EcosystemDr Wolfgang Philipp, Principal Adviser for Health and Crisis management, DG SANTE, European Commission
A Versatile Vaccine Manufacturing Platform for Pandemic Preparedness: From COVID-19 to Influenza
Novel Method: Uses riboflavin and UV light to inactivate viruses without damaging proteins—avoids harsh chemicals.
COVID-19 Vaccine: SolaVAX™ CoV-2 showed strong, lasting immunity and variant coverage in pre-clinical studies.
Flu Vaccine: SolaVAX-Flu-Q induced high antibody responses in mice against four seasonal strains.
Platform Potential: Enables rapid, broad-spectrum vaccine development for emerging threats.
Phase I Data for V-212, a Fully Synthetic, Serotype-Independent Vaccine Candidate targeting Streptococcus pneumoniae
Senior Representative, Virometix
Driving Trial Performance with Real-World Insights and Advanced Analytics
Cleaning Validation Strategies and Challenges for Vaccines
Senior Representative, Simtra Biopharma Solutions
Protective Pan-Betacoronavirus Neutralizing Antibodies by Vaccination
DNA Immunization for Immune Therapy Through Delivery and Lipid Formulation
Development Of 24-Valent Pneumococcal Conjugate Vaccine
AI-Powered Target Discovery for a Novel Polio Vaccine
Accelerating Vaccine Clinical Trials: The Power of Pratia's Decentralized and Comprehensive Site Network
Advancing Cancer Vaccines: LNP-Mediated Delivery Of Multi-Epitope mRNA Enables Favourable Safety And Efficacy In Tumor-Bearing Mice
New Approaches to Antigen Identification, Immunogenetics, Host-Pathogen Interactions
The Impact of AI Tools in Clinical Trials
Panel: Prove it's safe: Is this the new vaccine policy "norm?"
- th the traditional vaccine policy infrastructure in flux—most notably emerging guidance from FDA, disruption of long-standing ACIP processes, and threats to the vaccine injury compensation system— this panel will discuss these changes and their implications for vaccine access, healthy vaccine markets, and innovation. How do we best respond to these changes and how do we most effectively communicate to a confused public?
- Strategies for maintaining scientific integrity and public confidence in a fragmented system.
- The importance of medical societies in developing evidence-based vaccine recommendations.
- The role of new organizations (EVAT: Expert Vaccine Analysis Team and VIP: Vaccine Integrity Project) as independent sources of vaccine science
- An assessment of the health of vaccine markets and the future of innovation
- Emerging legal threats for providers and manufacturers
Topic to discuss include:
Update on US Legislation for Supply Chains – Will New Plans Bolster US Supply?
From Recommendation to Reality: Why Strong Vaccine Policy Still Falls Short at the Point of Care
- li>
- Exploring the gap between national vaccination goals and real-world delivery, and how digital health tools can translate policy into consistent clinical action.
A Novel Lipopeptide Platform for Pan-Coronavirus Vaccine Development
Defining Immunobridging: Nuances, Regulatory Precedent, and Use Cases for Accelerated Vaccine Access
Translating the rVSV Platform for Nipah and Marburg Vaccines
Panel: One Health, One Standard: Driving Global Regulatory Convergence
- Moving vaccines to market faster in emergency situations- Global regulatory harmonization – aligning with Europe and global markets- Understanding processes for innovative technologies
FDA Pre-Check Program: An Industry Perspective on Localising Manufacturing and Maintaining Quality
Addressing Declining Immunization Rates Through Digital Accessibility *Title TBC
A Global Roadmap for Durable, Broadly Protective, and Next-Generation Coronavirus Vaccines
Panel: Immunobridging for Accelerated Vaccine Access: From Preclinical Models to Real-World Application
· Defining Immunobridging– Use cases in outbreak scenarios and population expansion.
· Assay Development & Standardization– Challenges in T-cell vs. antibody assays
· Data Integration & AI Tools– Improving comparability and accessibility.
· Case Studies– MPOX, Nipah, MERS, Chikungunya.
· Academic vs. Operational Perspectives– Translating research into scalable solutions.
Understanding Biotherapeutic Function Through Integrated Characterization of Structure, Stability & Binding
Senior Representative, Nicoya Lifesciences
Innovating in Respiratory Vaccines: Analytical Insights into Pneumococcal Candidate Development
Panel: Climate Change and the Shifting Landscape of Infectious Diseases
- How is climate change affecting disease distribution and frequency?- What areas are at risk from emergence and re-emergence?- How can climate change data be integrated with disease surveillance and how is this informing planning and procurement for vaccination programs?- Reviewing the pipeline for vaccines against mosquito borne diseases – where are our priorities for vaccine R&D?- How do we predict the effect of climate change on vaccine distribution e.g. cold chain capabilities?
Development of an Affordable Pentavalent Meningococcal Conjugate Vaccine: The Importance of Carrier Protein and Antigen Manufacturing Strategies
Senior Representative, Primrose Bio
Panel: Platforms Are Out, Products Are In: What VCs & Private Investors Really Want
- is panel will explore the shifting priorities in venture capital investment within the vaccine and biotech space. Historically, platforms promised broad, long-term innovation, but today’s market increasingly favors tangible, indication-specific products. Is this a cyclical trend or a fundamental shift? Join leading VCs as they debate the future of biotech funding, the role of hype, and what startups must do to attract investment in a more cautious, product-driven landscape.
- Understand the current VC investment climate in biotech and vaccines.
- Explore the tension between platform-based innovation and product-focused funding.
- Discuss how hype and market cycles influence valuations and investor interest.
- Provide actionable insights for startups seeking VC attention.
Manufacturing for Domestic Health Security: Goals, Incentives, Strategic Partnerships
- li>
- ASPR-led update on centralizing domestic vaccine/API manufacturing
- Strategic goals and public-private incentives
- Emergency response challenges and solutions
The Crucial Role of Tone: Sustaining High Vaccine Uptake Through Effective Public Health Messaging
- li>
- Public health messaging tone is crucial, even in pro-vaccine areas.
- Focus on proactive misinformation prevention and effective message framing.
- Emphasizes maintaining strong community partnerships.
- Shares best practices from high-uptake areas to inform low-uptake strategies
Panel: Broadly Protective Vaccines – Where Are We?
- Continuing R&D against coronaviruses: has ‘COVID fatigue’ also stalled research and investment? - Target product profile: who, what and when?- Do we understand enough about circulating coronaviruses & other respiratory viruses like influenza to have sufficient coverage against high risk variants?- Stimulating mucosal immunity in non-naive populations and improving our understanding of correlates of protection.- Economic perspectives on funding BP vaccines – funding mechanisms, market dynamics
Panel: Human Challenge Models: A New Gold Standard?
- li>
- Evaluate HCMs as faster, cost-effective alternatives to Phase III trials, especially for outbreak-prone diseases.
- Share real-world examples from CEPI’s CHIM consortium and other global initiatives.
- Discuss regulatory and ethical frameworks for participant safety and trial approval.
- Explore operational challenges including infrastructure, biosafety, and assay standardization.
- Examine the role of immunobridging in translating animal data to human efficacy.
- Debate future potential of HCMs in mainstream vaccine licensure, including AI and biomarker integration.
Panel: Translating Public R&D Into Animal Health Innovation
- How do we identify vaccine research gaps and market gaps? Where do these methods overlap and where do they diverge?
- What are the challenges from the industry perspective on moving a research vaccine candidate to a marketable product?
- What are the challenges in implementing new technologies or improved vaccines in the face of a current profitable vaccine?
- What are the ideal characteristics of a vaccine candidate to move it to market from a biological perspective?
- What are the ideal characteristics of a vaccine candidate to move it to market from an administrative perspective?
- From an industrial marketing perspective, what is needed for coordination between countries?
Pneumococcal Vaccines: How Many Serotypes Do We Need?
From Fragile to Fortified: Building a Resilient Biopharma Supply Chain Through Pre-Competitive Collaboration
Global vaccine and biologics supply chains remain vulnerable to geopolitical shocks, raw material shortages, and capacity bottlenecks. This presentation introduces ATI’s BioMaP Consortium—a pre-competitive, industry-government collaboration designed to strengthen U.S. biopharmaceutical manufacturing resilience, continuity, and surge capacity. Attendees will learn how shared infrastructure, coordinated investment, and cross-sector execution models can transform supply chains from reactive to resilient.
Rapid, Precise, And Scalable Characterization of Plasmid Isoforms to Ensure Critical Quality Attributes In Vaccine Production
Senior Representative, Agilent
Create your personal agenda –check the favourite icon
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s Opening Remarks
Chair’s opening remarks
Underlying Mechanisms Of A Clinical-Stage Immune Focusing Platform
An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics
Beyond RSV: The Role of hMPV and Parainfluenza Viruses in Adult Respiratory Disease
Panel: Meeting the Challenges of Vaccine Preventable Diseases Across Major Functions of the Supply Chain Through Strategic, Integrated Approaches
Panel: Designing Clinical Trials for Emerging Threats
Manufacturing Next-Generation Vaccines: Scaling Up Outer Membrane Vesicle Production to GMP Standards
Strategies for the Reduction of Agricultural Methane Emissions
- li>
- Challenges in targeting methanogenic microbes across diverse gut ecosystems, as well as achieving high rates of methane-reduction efficiency
- Regulatory and practical challenges of deploying methane reducing vaccine
- Possible applications of methane-reducing technology to other organisms and greenhouse gases
Industrializing Personalized RNA: Continuous-Flow Manufacturing to Compress Time, Cost, and Risk
Fireside chat: Can AI Be Trusted with the Truth? Health Messaging in a Misinformation Age
Best Practices for Working with CMOs And Tech Transfer Success Stories
Development of a Broadly Protective, Recombinant Protein, Sarbecovirus Vaccine
Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant
Potential for Combination Respiratory Vaccines
Diversified funding models beyond USG
Rationally Designed Next-Generation Malaria Vaccine (FMP015) Adjuvanted with Army Liposomal Formulation Containing QS21
From Early-Stage Lab-Scale Process Development to Pilot and Commercial Scales: A Data-Driven Optimization Approach for a Multivalent Conjugate Vaccine Development and Its Commercialization
Immunological Imprinting and Dose Timing: Data-Driven Considerations for COVID-19 Strain Selection
COVID-Flu Combination Vaccine Development Updates
Innate Immunity: The Next Frontier in Vaccines
To Vaccinate or Not to Vaccinate: Are Vaccinations a Possible Tool for Prevention, Control or Elimination of H5N1 in Dairy Cattle?
From Public Funding to Public Health Impact: India’s Vaccine Innovation and Manufacturing Playbook
Empowering the Frontline: How Nurse-Led Innovation Builds Vaccine Confidence and Safer Delivery Models
AI-Powered Target Discovery for a Novel CMV Vaccine
Validation of Next Generation Sequencing Assays for Adventitious Virus Detection
Panel: Strain Selection for Respiratory Vaccines: Aligning Science, Strategy & Schedules
- li>
- Timing tensions between flu (Feb–Mar) and COVID (May–Jun) strain selection.
- Understanding the epidemiology and selective pressures on respiratory viruses informing strain selection times
- Platform disparities in speed to market (mRNA vs. protein vs. egg-based).
- Scientific debate over lineage-level vs. strain-level selection strategies.
- Impact of combo vaccines on aligning strain selection schedules.
- Variant unpredictability challenges the value of late-season selections
Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response
- li>
- Introduction & Context:o Challenges with mRNA vaccine durability and breadtho Emerging role of genetic adjuvantso Relevance to pandemic preparedness and immunological innovationModerator: Dr Jay Evans, Chief Scientific and Strategy Officer, Inimmune
- Talk 1 - mRNA genetic adjuvants for viral, bacterial, and cancer diseasesDr Heath Damron, Co-founder and Chief Scientific Officer, Montani Biotechnologies, Inc
- Talk 2 - Adjuvant Optimization and Population-Centric Approaches in mRNA Vaccine InnovationDr David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children’s Hospital
- Talk 3 - Il-1 genetic adjuvant enhances vaccine induced immunityDr Hardik Amin, Senior Scientist, University of Montana
- Discussion & Q&A Topics:o Mechanisms & Promise of Genetic Adjuvantso Enhancing mRNA Vaccine Breadth & Durabilityo Translational & Clinical Perspectiveso Where do genetic adjuvants fit in the current vaccine tech landscape?o Regulatory hurdles and funding gapso Opportunities for collaboration and future researchAll Speakers
Panel: Combining Respiratory Vaccines - Balancing Efficacy, Durability and Immunization Schedules
- What should we combine? Bi and Tri Pathogen vaccines.- What do we understand about efficacy, immunology and durability of combinations?- Balancing are we considering seasonality across diverse geographies?- Regulatory and policy considerations.
Panel: How Close Are We to Licensure of A CMV Vaccine? Lessons For Latent Virus Control
- What immunological and technical barriers remain in targeting CMV, and why has progress been so slow?- How are different platforms—mRNA, VLP, subunit, viral vectors—addressing the challenges of antigen complexity and needs of diverse patient groups?- How might progress in CMV vaccine R&D inform broader strategies for tackling other persistent viral infections?
Panel: Preparing for Rapid Generation of Emergency Evidence During Outbreaks
- cus: Lessons learned from implementing a multi-regional research preparedness program in Africa.
- Presentations and Discussion Points:o Developing a locally led, cross-regional approach to research preparednesso Key gaps in the rapid implementation of research during outbreaks—lessons from East and Central Africao Lessons from building sustainable, institution-led capacity for rapid trial readinesso Developing and implementing a mobile unit for interventional trials in an outbreako Ecosystem priming and preparedness for operational excellence to support evidence generation for outbreakso From surveillance signals to site strategy: Leveraging epidemiology to drive outbreak-responsive trials
The Hard Problem of Aggregation in Vaccines
Innate Immunity: The Next Frontier in Vaccines
Panel: Venture Philanthropy for Vaccines – A Powerful Engine to Do Good
- li>
- Explore how venture philanthropy bridges public health goals with private capital returns.
- Showcase successful case studies in vaccine development for cancer, T1D, and more.
- Discuss how these funds de-risk early science and catalyze VC and pharma engagement.
- Highlight the untapped potential in infectious diseases, AMR, and global health.
- Offer insights into future models of funding and collaboration in vaccinology
Panel: How Manufacturers are Responding to Decreasing Public Trust in Vaccines and Science
- Vaccine makers may help sustain trust and access amid funding cuts.
- Comms teams face reputational, misinformation, and workload challenges.
- Key tactics: reach hesitant groups, support providers, manage info gaps.
- Industry can help fill roles left by weakened public programs
Quality Evaluation of mRNA-LNP Vaccines by Innovative Biophysical Methods
Vaccines For Fungal Disease...Getting Closer
Keynote panel: Pandemic Proof: Forming Resilient Ecosystems for the Future
- li>
- How can international institutions lead and coordinate cross-border preparedness and response to health threats?
- What lessons from previous pandemics/ outbreaks can inform future global cooperation frameworks?
- How can global institutions lead and coordinate cross-border preparedness and response to health threats?
- How can surveillance infrastructure be harmonized with global partners?
- How are different institutions leveraging AI and real-world data to enhance early warning capabilities?
- What are the regulatory and ethical considerations in deploying AI for public health surveillance?
- How can real-world data support rapid vaccine adaptation and deployment in future pandemics?
- CEPI 3.0 strategy
Closing Keynote Panel: Rhetoric to Reality: New Administration’s Policies and the Vaccine Market
- li>
- Review each stage of the vaccine lifecycle: R&D, approval, manufacturing, distribution, and uptake.
- Analyze how new policies (e.g., agency changes, funding shifts, messaging) have disrupted these stages.
- Highlight political impacts on vaccine development and delivery.
- Aim to give stakeholders a clear, forward-looking view of the evolving vaccine market.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events